OncoMatch/Clinical Trials/NCT07173595
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Is NCT07173595 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies QLS2309 for relapsed or refractory hematologic malignancies.
Treatment: QLS2309 — This is a single-arm, open-label, multicenter, dose-escalation, dose-expansion and efficacy-expansion phase I clinical study to evaluate the tolerability, safety, pharmacokinetics and preliminary antitumor activity of QLS2309 injection in patients with CD70+ relapsed/refractory hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD70 overexpression (CD70+)
CD70+ relapsed/refractory hematologic malignancies
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CD70-related antibodies, antibody-conjugated drugs (ADCs) or cell therapy products
Prior treatment with CD70-related antibodies, antibody-conjugated drugs (ADCs) or cell therapy products
Cannot have received: chemotherapy, biological therapy, endocrine therapy, immunotherapy, monoclonal antibodies
Known history of chemotherapy, biological therapy, endocrine therapy, immunotherapy, monoclonal antibodies, etc. within 4 weeks
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify